# Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study

> **NCT00462423** · PHASE2 · COMPLETED · sponsor: **Lynn E. Spitler, MD** · enrollment: 50 (actual)

## Conditions studied

- Metastatic Malignant Melanoma

## Interventions

- **DRUG:** Avastin
- **DRUG:** Abraxane

## Key facts

- **NCT ID:** NCT00462423
- **Lead sponsor:** Lynn E. Spitler, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2011-04
- **Final completion:** 2012-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2014-01-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00462423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00462423, "Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00462423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*